Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>=18 and \<=65 years of age~* Body weight \>=40 and \<=125 kg~* Documented history of HIV infection for greater than 6 months prior to Day 1~* On an optimized anti-retroviral treatment regimen (OTR) with stable HIV disease with CD4 \>=200 cells/µL and HIV-1 RNA viral load \<50 copies/mL~* Documented chronic hepatitis C (CHC) genotype 1 infection (greater than 6 months prior to Day 1)~* Use of acceptable methods of contraception 2 weeks prior to Day 1 and at least 6 months or longer after treatment~* Liver biopsy with histology consistent with CHC and no other etiology~Exclusion Criteria:~* Participants who received prior treatment for hepatitis C other than herbal remedies except those with known hepatotoxicity~* Coinfected with hepatitis B virus (Hepatitis B surface antigen (HBsAg) positive) and/or demonstrating signs and symptoms consistent with concomitant infection~* Evidence of decompensated liver disease~* Participants who have changed their anti-retroviral regimen within the last 3 months prior to Day 1 or had first initiated anti-retroviral therapy within the last 6 months prior to Day 1~* Use of certain HIV medications will not be allowed. Medications will be reviewed by the Investigator~* History of clinically significant opportunistic infections (except oral thrush) within the last year prior to Day 1~* Current evidence of substance abuse within 3 years of the Screening Visit~* History of a clinical diagnosis within the past 6 months of substance abuse prior to Day 1~* Participants receiving opiate agonist substitution therapy but not enrolled in an opiate substitution maintenance program~* History of marijuana use deemed excessive by the Investigator~* Infected with HIV-2~* Use of any HIV protease inhibitor without the coadministration of ritonavir within one month of Day 1 and throughout the period of the trial~* Participants receiving any of the following medication(s) within 2 weeks prior to the Day 1 visit: alfuzosin, antiarrhythmics (amiodarone, bepridil, flecainide, propafenone, and quinidine), ergot derivatives, cisapride, lovastatin, simvastatin, pimozide, triazolam, and orally administered midazolam.~Key Laboratory Exclusion Criteria:~* Hematologic, biochemical, and serologic criteria (growth factors may not be used to achieve trial entry requirements):~  * Hemoglobin \<11 g/dL for females and \<12 g/dL for males~ * Neutrophils \<1500/mm\^3 (blacks/African-Americans: \<1200/mm\^3)~ * Platelets \<100,000/mm\^3~ * Direct bilirubin \>1.5 x ULN (upper limit of normal) of the laboratory reference range. Total bilirubin \>1.6 mg/dL unless history of Gilbert's disease or antiretroviral regimen contains atazanavir. If Gilbert's disease is the proposed etiology, this must be documented in the participant's chart~* Alpha fetoprotein (AFP):~  * AFP \>100 ng/mL OR~ * AFP 50 to 100 ng/mL (requires a liver ultrasound and participants with findings suspicious for hepatocellular carcinoma are excluded)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- PegIFN-2b + RBV (Type: PLACEBO_COMPARATOR): PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600-1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by placebo to boceprevir plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up (Control Arm). Participants who do not achieve HCV-RNA \<9.3 IU/mL by Treatment Week 24 (TW24) are eligible to cross-over and receive boceprevir along with the PegIFN-2b and RBV for up to 44 weeks.
- PegIFN-2b + RBV + Boceprevir (Type: ACTIVE_COMPARATOR): PegIFN-2b (1.5 µg/kg/week subcutaneously) plus RBV (600- 1400 mg/day, orally, divided into two daily doses) for 4 weeks followed by boceprevir (800 mg, orally, 3 times per day) plus PegIFN-2b/RBV for 44 weeks with 24 weeks post-treatment follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).